Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells

Cancer Research

Volumn 57, Issue 17, 1997, Pages 3804-3811

  Daly, John M ^a   Jannot, Christian B ^a   Beerli, Roger R ^a   Graus Porta, Diana ^a   Maurer, Francisca G ^a   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR;

APOPTOSIS; ARTICLE; BREAST TUMOR; DIMERIZATION; DOWN REGULATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; G2 PHASE; GENES, ERBB-2; GLYCOPROTEINS; HUMANS; NEUREGULINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0030768379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Coussens, L., Yang-Feng, T. L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
2. Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., and Hynes, N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
3. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
4. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta, 1198: 165-184, 1994.
5. Wen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Ben-Levy, R., Koski, R. A., Lu, H. S., and Yarden, Y. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69: 559-572, 1992.
6. erbB2. Science (Washington DC), 256: 1205-1210, 1992.
7. Carraway, K. L., III, Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., and Cerion, R. A. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269: 14303-14306, 1994.
8. erbB4. Nature (Lond.), 366: 473-475, 1993.
9. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III. Coexpression of erbB2 and erbB3 proteins reconstitute a high affinity receptor for heregulin. J. Biol. Chem., 269: 14661-14665, 1994.
10. Jones, F. E., Jerry, D. J., Guarino, B. C., Andrews, G. C., and Stern, D. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth & Differ., 7: 1031-1038, 1996.
11. Marte, B. M., Jeschke, M., Graus-Porta, D., Taverna, D., Hofer, P., Groner, B., Yarden, Y., and Hynes, N. E. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol. Endocrinol., 9: 14-23, 1995.
12. Ram, T. G., Kokeny, K. E., Dilts, C. A., and Ethier, S. P. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-1 in human mammary epithelial cells. J. Cell. Physiol., 163: 589-596, 1995.
13. Graus-Porta, D., Beerli, R. R., and Hynes, N. E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol., 15: 1182-1191, 1995.
14. Beerli, R. R., and Hynes, N. E. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem., 271: 6071-6076, 1996.
15. Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Huijens, A., Fendly, B. M., Bauer, K. D., and Sliwkowski, M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
16. erbB2. Science (Washington DC), 249: 1552-1555, 1990.
17. Bacus, S. S., Huberman, E., Chin, D., Kiguchi, K., Simpson, S., Lippman, M., and Lupu, R. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth & Differ., 3: 401-411, 1992.
18. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Ben-Levy, R., and Yarden, Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentialion of mammary tumor cells. Cell, 69: 205-216, 1992.
19. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
20. Harwerth, I-M., Wels, W., Marte, B. M., and Hynes, N. E. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J. Biol Chem., 267: 15160-15167, 1992.
21. Harwerth, I-M., Wels, W., Schlegel, J., and Hynes, N. E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer, 68: 1140-1145, 1993.
22. Kasprzyk, P. G, Song, S. U., DiFiore, P. P., and King, C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.
23. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 695-706, 1985.
24. Beerli, R. R., Wels, W., and Hynes, N. E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem., 269: 23931-23936, 1994.
25. Jannot, C. B., Beerli, R. R., Mason, S., Gullick, W. J., and Hynes, N. E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene. 13: 275-282, 1996.
26. Deshane, J., Loechel, F., Conry, R. M., Siegel, G. P., King, C. R., and Curiel, D. T. Intracellular single-chain antibody directed against erbB2 down-regulate cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther., 1: 332-337, 1994.
27. Wen, D., Suggs, S. V., Karunagaran, D., Liu, N., Cupples, R. L., Luo, Y., Janssen, A. M., Ben-Baruch, N., Trollinger, D. B., Jacobsen, V. L., Meng, S-Y., Lu, H. S., Hu, S., Chang, D., Yang, W., Yanigahara, D., Koski, R. A., and Yarden, Y. Structural and functional aspects of the multiplicity of Neu differentiation factor. Mol. Cell. Biol., 14: 1909-1919, 1994.
28. Hynes, N. E., Gerber, H. A., Saurer, S., and Groner, B. Overexpression of the c-erbB2 protein in human breast tumor cell lines. J. Cell. Biochem., 39: 167-173, 1989.
29. Druker, B. J., Mamon, H. J., and Roberts, T. M. Oncogenes, growth factors and signal transduction. N. Engl. J. Med., 321: 1383-1391, 1989.
30. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors and multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
31. Sherwood, S. W., and Schimke, R. T. Cell cycle analysis of apoptosis using flow cytometry. In: Methods in Cell Biology, Vol. 46, pp. 7-97. San Diego: Academic Press, 1995.
32. Idziorek, T., Estaquier, J., De Bels, F., and Ameisen, J. YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J. Immunol. Methods, 185: 249-258, 1995.
33. Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., and Hynes, N. E. Neu differentiation factor activation of ErbB3 and ErbB4 is cell specific and displays a differential requirement for ErbB2. Mol. Cell. Biol., 15: 6496-6505, 1995.
34. Lee, C. S. L., Hall, R. E., Alexander, I. E., Koga, M., Shine, J., and Sutherland, R. L. Inverse relationship between estrogen receptor and EGF receptor mRNA levels in human breast cancer cell lines. Growth Factors, 3: 97-103, 1990.
35. HER2 monoclonal antibodies. Cancer Immunol., 37: 255-263, 1993.
36. Jeschke, M., Wels, W., Dengler, W., Imber, R., Stoecklin, E., and Groner, B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer, 60: 730-739, 1995.
37. erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
38. Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J., 12: 961-971, 1993.
39. Goldman, R., Ben-Levy, R., Peles, E., and Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29: 11024-11028, 1990.
40. Martin, S. J., Reutelingsperger, C. P. M., McGahon, A. J., Rader, J., van Schie, R. C. C. A., LaFace, D., and Green, D. R. Early redistribution of plasma membrane phosphatidlyserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by Overexpression of Bcl-2 and Abl. J. Exp. Med., 182: 1545-1556, 1995.
41. Chammas, R., Taverna, D., Cella, N., Santos, C., and Hynes, N. E. Laminin and tenascin assembly and expression regulate HC11 mouse mammary cell differentiation. J. Cell Sci., 107: 1031-1040, 1994.
42. Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B., Seger, N. E., and Yarden, Y. ErbB-2 is a common signaling subunit of NDF-and EGF-receptors: implications for breast cancer. EMBO J., 15: 254-264, 1996.
43. Marte, B. M., Graus-Porta, D., Jeschke, M., Fabbro, D., Hynes, N. E., and Taverna, D. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene, 10: 167-175, 1995.
44. Alper, O., Yamaguchi, K., Hitomi, J., Honda, S., Matsushima, T., and Abe, K. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SKBR3. Cell Growth & Differ., 1: 591-599, 1990.
45. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15: 2452-2467, 1996.
46. Baulida, J., Kraus, M. H., Alimandi, M., DiFiore, P. P., and Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem., 271: 5251-5257, 1996.
47. Chen, X., Levkowitz, G., Tzahar, E., Karunagaran, D., Lavi, S., Ben-Baruch, N., Leitner, O., Ratzkin, B. J., Bacus, S. S., and Yarden, Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem., 271: 7620-7629, 1996.
48. Wels, W., Harwerth, I-M., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody toxin specific for the erbB-2 receptor. Cancer Res., 52: 6310-6317, 1992.
49. Wels, W., Beerli, R., Hellmann, P., Schmidt, M., Marte, B. M., Kornilova, E. S., Hekele, A., Mendelsohn, J., Groner, B., and Hynes, N. E. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptors. Int. J. Cancer, 60: 137-144, 1995.
50. Bacus, S. S., Kiguchi, K., Chin, D., King, C. R., and Huberman, E. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog., 3: 350-362, 1990.
51. Marth, C., Cronauer, M. V., Doppler, W., Öfner, D., Ullrich, A., and Daxenbichler, G. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int. J. Cancer, 50: 64-68, 1992.
52. Bacus, S. S., Gudkov, A. V., Zelnick, C. R., Chin, D., Stern, R., Stancovski, I., Peles, E., Ben-Baruch, N., Farbstein, H., Lupu, R., Wen, D., Sela, M., and Yarden, Y. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule I: implications for mammary tumors. Cancer Res., 53: 5251-5261, 1993.
53. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J., 16: 1647-1655, 1997.
54. Buchdunger, E., Mett, H., Trinks, U., Regenass, U., Müller, M., Meyer, T., Beilstein, P., Wirz, B., Schneider, P., Traxler, P., and Lydon, N. B. 4,5-Bis(4-fluoroanilino)-phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.
55. c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther., 1: 99-105, 1994.
56. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.